Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipid lowering and Alzheimer disease risk: A mendelian randomization study.

Annals of neurology - 1 Jan 2020

Williams Dylan M, Finan Chris, Schmidt Amand F, Burgess Stephen, Hingorani Aroon D

Abstract excerpt

OBJECTIVE: To examine whether genetic variation affecting the expression or function of lipid-lowering drug targets is associated with Alzheimer disease (AD) risk, to evaluate the potential impact of long-term exposure to corresponding therapeutics. METHODS: We conducted Mendelian randomization analyses using variants in genes that encode the protein targets of several approved lipid-lowering drug classes: HMGCR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alzheimer Disease
Share to Apolipoprotein B-100

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl CoA Reductases

Share to Membrane Transport Proteins

Share to Mendelian Randomization Analysis

Share to Models, Genetic

Share to Proprotein Convertase 9

Source

Open in PubMed Open full text

Identifiers

PMID: 31714636
DOI: 10.1002/ana.25642
PMCID: PMC6944510

Genes

PCSK9
APOB
HMGCR
NPC1L1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipid lowering and Alzheimer disease risk: A mendelian randomization study.PMID 31714636Read ↗

Causal relationship between cholesterol-lowering therapy and Alzheimer Disease: evidence from genetic correlation and Mendelian randomization studySemantic proximity Read ↗

Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization.Semantic proximity Read ↗

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive FunctionSemantic proximity Read ↗

Genetic Associations Between Modifiable Risk Factors and Alzheimer DiseaseSemantic proximity Read ↗

Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a Mendelian randomization analysis.Semantic proximity Read ↗

The role of lipid species in Alzheimer's disease onset: A comprehensive Mendelian randomization analysis.Semantic proximity Read ↗

Lipids, Apolipoproteins, Statins, and Intracerebral Hemorrhage: A Mendelian Randomization StudySemantic proximity Read ↗

LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization StudySemantic proximity Read ↗

Angiotensin-converting enzyme inhibition and Alzheimer’s disease: Findings from proteome-wide Mendelian randomization and a large prospective cohort studySemantic proximity Read ↗

Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.Semantic proximity Read ↗

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.Semantic proximity Read ↗

A phenome-wide hunt for risk factors of Alzheimer's disease: from metabolic clues to neuroimaging evidence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.